Trimurthi Ltd

Novelix Pharmaceuticals Ltd announced its unaudited standalone financial results for the quarter ended June 30, 2026. The Board of Directors approved these results along with the limited review report from the auditors. The meeting to approve the results commenced at 05:00 p.m. (IST) and concluded at 05:35 p.m. (IST). The company also confirmed that the information is available on its website. The results were prepared in accordance with Indian Accounting Standard 34.

Novelix Pharmaceuticals Ltd announced that its Board of Directors, in a meeting held on August 13, 2026, approved the standalone unaudited financial results for the quarter ended June 30, 2026. The meeting also reviewed the limited review report associated with these results. The company was formerly known as Trimurthi Limited. The board meeting commenced at 5:00 PM and concluded at 5:35 PM.

Novelix Pharmaceuticals Ltd has announced a Board of Directors meeting scheduled for August 13, 2026. The primary agenda item is to consider and approve the unaudited standalone financial results for the quarter ended June 30, 2026, along with the auditor's limited review report. Additionally, the meeting will address any other matters with the chair's permission. In compliance with SEBI regulations and the company's insider trading code, the trading window for designated persons and their immediate relatives will be closed from July 1, 2026, until 48 hours after the board meeting concludes.

Novelix Pharmaceuticals Ltd has disclosed a substantial acquisition of shares by its promoter group. Vupparapalli Chandrasekhar Reddy and Vupparapalli Pavani, acting as Persons Acting in Concert (PAC), have acquired 7,75,000 equity shares. This acquisition, totaling 1.29% of the voting rights, was executed through the conversion of warrants issued via preferential allotment on July 9, 2026. Following this transaction, the promoter group's total holding in Novelix Pharmaceuticals has increased, impacting the company's diluted share capital. The filing is made under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011.

Novelix Pharmaceuticals Ltd has disclosed the allotment of 100,000 equity shares to Neha Gattu on July 9, 2026. This allotment is a result of the conversion of warrants previously issued through a preferential allotment. Following this, the total diluted share capital of the company has increased. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The acquisition represents a small percentage of the total voting capital.

Srinidhi Fine-Chemicals LLP and Narahari Belide have disclosed an increase in their shareholding in Novelix Pharmaceuticals Ltd following the conversion of warrants into equity shares. The transaction, which occurred on July 9, 2026, was executed via preferential allotment. Post-acquisition, Srinidhi Fine-Chemicals LLP holds 10,002,000 shares (35.13% voting rights), and Narahari Belide holds 1,200,000 shares (4.21% voting rights). The total diluted share capital of Novelix Pharmaceuticals Ltd after the acquisition stands at Rs. 28,47,00,000, comprising 28,470,000 equity shares of Rs. 10 each.

Novelix Pharmaceuticals Ltd has disclosed a significant shareholding change involving Neha Gattu, who was allotted 100,000 equity shares on July 9, 2026. This allotment occurred pursuant to the conversion of warrants previously issued through a preferential allotment. The acquisition increases the total diluted share capital of the company. The filing, made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, details the holdings of Gattu Gnana Prakash, Arati Gattu, and Neha Gattu before and after the acquisition. The total equity share capital of Novelix Pharmaceuticals Ltd post-acquisition stands at ₹28,47,00,000, comprising 28,470,000 equity shares of ₹10 each.

Srinidhi Fine-Chemicals LLP and Narahari Belide have disclosed an acquisition of equity shares in Novelix Pharmaceuticals Ltd. The acquisition, totaling 25,00,000 equity shares (2.93% stake), occurred on July 9, 2026, through the conversion of warrants issued via preferential allotment. Following this, Srinidhi Fine-Chemicals LLP holds 10,002,000 shares (36.68% stake) and Narahari Belide holds 1,200,000 shares (4.40% stake). The total holding of the acquirers along with persons acting in concert now stands at 11,202,000 shares, representing 39.35% of the company's total voting capital. The company's equity share capital post-acquisition is Rs. 28,47,00,000.

Novelix Pharmaceuticals Ltd announced the allotment of 45,75,000 equity shares following a board meeting on July 9, 2026. This includes 33,75,000 shares issued upon conversion of warrants to promoter and promoter group holders at ₹20 each, and 12,00,000 shares issued via preferential private placement to non-promoters at ₹57 each. The company received ₹50,625,000 from the warrant conversion. This allotment increases the company's paid-up equity capital.

The Board of Directors of Novelix Pharmaceuticals Ltd, in a meeting on July 9, 2026, approved the allotment of 3,375,000 equity shares to promoter/promoter group upon warrant conversion at ₹20 each, raising ₹5.06 crore. Additionally, 1,200,000 equity shares were allotted to non-promoters via preferential issue at ₹57 each, raising ₹6.84 crore. In total, 4,575,000 new equity shares were allotted, increasing the company's paid-up equity capital from ₹23.90 crore (23,895,000 shares) to ₹27.27 crore (27,270,000 shares).